Click image to enlargeThe purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Criteria:--Have a diagnosis of psoriatic arthritis (PsA) for at least 6 months prior
--Must have magnetic resonance imaging (MRI)-confirmed PsA axial disease
--Must have active plaque psoriasis
--Must NOT have other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to RA, AS, non-radiographic-AS(this does not include a primary diagnosis of PsA with spondylitis), SLE, or Lyme disease
--Must NOT have previously received any biologic treatment
--Must have NEVER received a Janus kinase (JAK) inhibitor
--Must have NEVER received any systemic immunosuppressants within 4 weeks of the first administration of study intervention